Adapted from Roth et al. 2015 and Praluent® SmPC.1,2
Although many patients requiring lipid lowering therapies are not experienced with self-injected medication, a real-world clinical study has demonstrated that the pre-filled pen device is well-accepted by patients and healthcare practitioners1
*Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in Praluent® phase 3 trials.
**Evaluated in a cross-sectional, non-interventional study involving 400 patients enrolled in Praluent® phase 3 trials. The I-TAQ data is a 22-item, self-administered questionnaire, developed as a measure of injection-treatment acceptance for use in patients who inject their medications via subcutaneous injections.
I-TAQ=injection-treatment acceptance questionnaire; PIL=patient information leaflet; SmPC=summary of product characteristics.